The CDC has issued an official press release on this issue. They, and the FDA, are working with vaccine manufacturers to pass along to healthcare providers current updates on the situation and would like to postpone any "mass" vaccinations until November, stating that plans need to be implemented to insure that those most in need of the vaccinations somehow are provided for.
The amount of vaccine available is complicated by two important factors: 1) the yield for this year's influenza vaccine A(H3N2) component appears to be lower than expected which limits the supply that can be developed in time for this flu season and, 2) other manufacturing issues. Manufacturers are working closely with the FDA to address these issues.
What other manufacturing issues? Have those issues been defined by anyone? I have been unable to locate any information regarding this. But I do believe this brings up several issues that need to be looked at closely. The controversy around vaccinations is only thickening.
The requirement for flu vaccine should not have been a surprise for the vaccine manufacturing companies. Every year flu vaccines are made and the population of the United States has not varied from year to year in any significant amount.
The controversy around vaccinations is becoming a very volatile situation. Recently evidence has shown that at least one, and possibly two vaccinations given to children, have caused or at least contributed to the development of juvenile diabetes or asthma. The controversy around the MMR vaccine with Autistic children is a boiling cauldron of dispute.
Go To Page: 1 2
| Here's the follow-up discussion on this article: | View all related messages |
For a complete listing of article comments, questions, and other discussions related to Adelle Vancil Tilton's Public Health Issues topic, please visit the Discussions page.